Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million
27 Julho 2023 - 8:00AM
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on
patients treated by ear, nose and throat (ENT) and allergy
specialists, today announced preliminary XHANCE® (fluticasone
propionate) net product revenue of $19.5 million for the three
months ended June 30, 2023.
“Our preliminary second quarter net product
revenue of $19.5 million contributes to a first half 2023
performance that exceeded our initial expectations,” stated CEO
Ramy Mahmoud. “We look forward to providing a complete update of
our recent commercial performance and regulatory progress on the
tenth of August.”
The financial information included in this release is
preliminary and is subject to change. The Company expects to report
full financial results for the second quarter of 2023 and corporate
updates, including full year 2023 net product revenue guidance,
before market open on Thursday, August 10, 2023.
Company to Host Conference Call
Members of the Company’s leadership team will host a conference
call to discuss financial results and corporate updates. The call
is scheduled to start at 8:00 a.m. Eastern Time on Thursday, August
10, 2023.
Participants may access the conference call live
via webcast by visiting the Investors section of Optinose’s website
at http://ir.optinose.com/event-calendar. To participate via
telephone, please register in advance at this link. Upon
registration, all telephone participants will receive a
confirmation email detailing how to join the conference call,
including the dial-in number and a personal PIN that can be used to
access the call. In addition, a replay of the webcast will be
available on the Company website for 60 days following the
event.
About OptinoseOptinose is a specialty
pharmaceutical company focused on serving the needs of patients
cared for by ear, nose, and throat (ENT) and allergy specialists.
To learn more, please visit www.optinose.com or follow us on
Twitter and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of
1995. All statements that are not historical facts are hereby
identified as forward-looking statements for this purpose and
include, among others, statements relating to: preliminary XHANCE®
net product revenue of $19.5 million for the quarter ended June 30,
2023; the Company’s expectation to report full financial results
for the second quarter of 2023 and corporate updates, including
full year 2023 net product revenue guidance, before market open on
Thursday, August 10, 2023; and other statements regarding the
Company's future operations, financial performance, financial
position, prospects, objectives; and other future events.
Forward-looking statements are based upon management’s current
expectations and assumptions and are subject to a number of risks,
uncertainties and other factors that could cause actual results and
events to differ materially and adversely from those indicated by
such forward-looking statements including, among others: the
potential for preliminary XHANCE net product revenue for the
quarter ended June 30, 2023 to change in connection with the
finalization of the Company’s financial results for the second
quarter of 2023; and the risks, uncertainties and other factors
discussed under the caption "Item 1A. Risk Factors" and elsewhere
in the Company’s most recent Form 10-K and Form 10-Q filings with
the Securities and Exchange Commission - which are available at
www.sec.gov. As a result, you are cautioned not to place undue
reliance on any forward-looking statements. Any forward-looking
statements made in this press release speak only as of the date of
this press release, and the Company undertakes no obligation to
update such forward-looking statements, whether as a result of new
information, future developments or otherwise.
Optinose Investor ContactJonathan
Neelyjonathan.neely@optinose.com267.521.0531
OptiNose (NASDAQ:OPTN)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
OptiNose (NASDAQ:OPTN)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024